Creative BioMart to Present at BPS 2025 Annual Meeting | February 15-19, 2025

Recombinant Human TNFRSF18 Protein (Gln26-Glu161), N-His tagged

Cat.No. : TNFRSF18-0682H
Product Overview : Recombinant Human CD357/TNFRSF18/GITR (Gln26-Glu161) fused with the N-His tag was expressed in E. coli.
  • Specification
  • Gene Information
  • Related Products
  • Download
Source : E. coli
Species : Human
Tag : His
Form : Lyophilized powder/frozen liquid
Molecular Mass : 16.84 kDa
Protein length : Gln26-Glu161
Purity : >90% as determined by SDS-PAGE.
Notes : For research use only.
Storage : Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 centigrade for one week.
Store at -20 to -80 centigrade for twelve months from the date of receipt.
Storage Buffer : 0.01M PBS, pH 7.4, 0.02% NLS
Reconstitution : Reconstitute in sterile water for a stock solution.
Shipping : They are shipped out with dry ice/blue ice unless customers require otherwise.
Gene Name : TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Homo sapiens (human) ]
Official Symbol : TNFRSF18
Synonyms : TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18; AITR; CD357; GITR; activation-inducible TNFR family receptor; glucocorticoid-induced TNFR-related protein; TNF receptor superfamily activation-inducible protein; GITR-D;
Gene ID : 8784
mRNA Refseq : NM_004195
Protein Refseq : NP_004186
MIM : 603905
UniProt ID : Q9Y5U5

Not For Human Consumption!

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
12/20/2021

    This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

    03/05/2020

      Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

      10/01/2017

        The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

        Q&As (5)

        Ask a question
        What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment? 12/20/2022

        Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

        Are there any approved TNFRSF18-targeted therapies for cancer treatment? 06/29/2019

        As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

        Are there potential side effects associated with TNFRSF18-targeted therapies? 12/30/2018

        Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

        How can TNFRSF18-targeted therapies potentially improve cancer outcomes? 05/05/2018

        TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

        Can TNFRSF18-targeted therapies be used in combination with other immunotherapies? 05/20/2016

        Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.

        Ask a Question for All TNFRSF18 Products

        Required fields are marked with *

        My Review for All TNFRSF18 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2025 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends